Financial Performance - Revenue for the six months ended September 30, 2022, was HKD 20,021,000, a decrease of 24.5% compared to HKD 26,618,000 for the same period in 2021[4] - The company reported a loss of HKD 3,331,000 for the six months ended September 30, 2022, compared to a profit of HKD 1,900,000 for the same period in 2021[4] - Basic loss per share for the six months ended September 30, 2022, was HKD (0.63), compared to HKD 0.06 for the same period in 2021[6] - The group reported a loss of HKD (3,305) thousand in total comprehensive income for the period, compared to a loss of HKD (3,313) thousand in the previous year[11] - For the six months ended September 30, 2022, the company reported a loss attributable to owners of the company of HKD 3,305,000, compared to a profit of HKD 1,755,000 for the same period in 2021[33] - The group recorded a loss attributable to owners of the company of HKD 3.3 million for the six months ended September 30, 2022, compared to a profit of HKD 1.8 million for the same period in 2021[65] Assets and Liabilities - Total assets decreased to HKD 25,744,000 as of September 30, 2022, down from HKD 30,091,000 as of March 31, 2022[9] - The company's net asset value was HKD 10,866,000 as of September 30, 2022, compared to HKD 14,179,000 as of March 31, 2022[9] - The company’s total liabilities as of September 30, 2022, were HKD 28,266,000, slightly down from HKD 29,863,000 as of March 31, 2022[9] - Total equity as of September 30, 2022, was HKD 10.9 million, down from HKD 14.2 million as of March 31, 2022[81] Cash Flow - The operating cash generated was HKD 862 thousand, down from HKD 1,860 thousand in the previous year, reflecting a decline of 53.8%[14] - The net cash used in investing activities was HKD (758) thousand, compared to HKD (1,547) thousand in the prior year, indicating a reduction of 51%[14] - The net cash used in financing activities was HKD (3,851) thousand, a decrease from HKD (13,945) thousand in the previous year, showing a significant improvement[14] - Cash and bank balances as of September 30, 2022, were HKD 9.8 million, a decrease from HKD 14.2 million as of March 31, 2022[81] Employee Costs - The company incurred employee costs of HKD 10,420,000 for the six months ended September 30, 2022, a decrease of 10.1% from HKD 11,591,000 for the same period in 2021[4] - Total employee costs amounted to HKD 10,420 thousand, a decrease from HKD 11,591 thousand in the previous year, indicating a reduction of 10.1%[26] - Employee costs decreased by HKD 1.2 million or 10.1% to HKD 10.4 million for the six months ended September 30, 2022, compared to HKD 11.6 million for the same period in 2021[72] Revenue Breakdown - The revenue breakdown includes medical consultation services at HKD 0.5 million (2.5%), prescription and dispensing services at HKD 4.4 million (22.2%), and treatment services at HKD 15.1 million (75.3%) for the six months ended September 30, 2022[64] - The group's revenue for the six months ended September 30, 2022, decreased by HKD 6.6 million or 24.8% to HKD 20.0 million, compared to HKD 26.6 million for the same period in 2021[69] Government Support - The group received government subsidies of HKD 829 thousand under the "Employment Support Scheme" to mitigate the impact of the COVID-19 pandemic[25] Share Capital and Options - The company had 396,736,000 ordinary shares in issue as of September 30, 2022, with a share capital of HKD 3,967,000[41] - No share options were exercised or cancelled during the six months ended September 30, 2022, and 4,000,000 share options expired during the same period[49] - The share options plan details indicate a total of 2,800,000 options available as of September 30, 2022[94] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the interim financial statements for the six months ending September 30, 2022, and found them compliant with applicable accounting standards and GEM listing rules[108] - The company has adopted the corporate governance code as per GEM listing rules and has complied with it during the six months ending September 30, 2022[101] Future Outlook - Despite the challenges posed by the COVID-19 pandemic, the company remains cautiously optimistic about future performance due to a solid customer base and good reputation in the industry[67] - The company aims to introduce new services and products as a key driver for business growth and to maintain competitiveness in the market[67] - The group continues to focus on enhancing online consultation services and e-commerce platforms for skincare products to adapt to the new normal[64] Miscellaneous - The company did not recommend an interim dividend for the six months ended September 30, 2022, compared to no dividend in 2021[31] - The group had no significant investments or capital asset plans as of September 30, 2022[83] - The group had no significant contingent liabilities as of September 30, 2022[88] - No significant events occurred after the reporting period[60] - The company has not disclosed any new strategies or market expansions in the provided documents[96] - The company has not reported any violations of the trading rules for directors during the six months ending September 30, 2022[104] - No directors or major shareholders were aware of any direct or indirect business interests that could compete with the group as of September 30, 2022[100]
密迪斯肌(08307) - 2023 - 中期财报